



**edap tms**  
Bringing New Horizons to Therapy

## **EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024**

Mar 13, 2024

*Company to host conference call and webcast on Wednesday, March 27<sup>th</sup> at 8:30am EDT*

LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27<sup>th</sup>, 2024.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

### **Call Details:**

Date: Wednesday, March 27<sup>th</sup>  
Time: 8:30 am EDT  
Domestic: 1-877-451-6152  
International: 1-201-389-0879  
Passcode: 13744102  
CallMe™ [LINK](#) (active 15 minutes prior to conference call)  
Webcast: [https://viavid.webcasts.com/starthere.jsp?ei=1653981&tp\\_key=0c7b100f3f](https://viavid.webcasts.com/starthere.jsp?ei=1653981&tp_key=0c7b100f3f)

### **About EDAP TMS SA**

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, [us.hifu-prostate.com](http://us.hifu-prostate.com) and [www.focalone.com](http://www.focalone.com).

### **Company Contact**

Blandine Confort  
Investor Relations / Legal Affairs  
EDAP TMS SA  
+33 4 72 15 31 50  
[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

### **Investor Contact**

John Fraunces  
LifeSci Advisors, LLC  
(917) 355-2395  
[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)